fashion -WSS

fashion

author：Wikipedia 2025-09-30 17:27:56 - browse：7114

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Tori Bowie and the unacceptable rates of Black maternal death
Next article： Medicare innovation center doesn’t save money, experts say

explore

WSS

After Optum profits sink, UnitedHealth makes changes

Bird flu researchers hone in on Finland’s mink farms

6 solutions to address cancer drug shortages and others

Mark Cuban is blaming the wrong people for high drug costs

WHO recommends second malaria vaccine

CDC picks Alphabet's Verily for wasterwater surveillance contract

focus

fashion

hotspot

How one medical school became remarkably diverse

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

IVG is promising — but it won’t replace IVF quite yet

As demand for Covid shots wanes, Moderna seeks its next success

Illinois Supreme Court finds assault weapons ban constitutional

Sports medicine is finally prioritizing gender equality

Experts study whether long Covid risk adds up with each reinfection

What does generative AI mean for health care? We asked experts

BMS, looking to build heart drug business, turns to AI for diagnosis

hotspot

Readout Newsletter: Biotech news, Wall Street disappointment, Lilly's drug delays

Illumina slashes 2023 revenue projections yet again

Medicare innovation center doesn’t save money, experts say

IVG is promising — but it won’t replace IVF quite yet

Flu, Covid vaccination rates decline, new survey data show

Flu, Covid vaccination rates decline, new survey data show

explore

focus

leisure time

knowledge